Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma

Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are CD19-targeted chimeric antigen receptor (CAR) T cells approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). We performed a retrospective study to evaluate safety and efficacy of axi-cel and tisa-cel outside the sett...

Descripción completa

Detalles Bibliográficos
Autores: Kwon, Mi, Iacoboni, Gloria, Reguera, Juan Luís, López Corral, Lucía, Hernani Morales, Rafael, Ortiz-Maldonado Gibson, Valentín, Guerreiro, Manuel, Caballero, Ana Carolina, Guerra Domínguez, Luisa, Sánchez Pina, Jose Maria, Mussetti, Alberto, Sancho, Juan Manuel, Bastos Oreiro, Mariana, Catala, Eva, Delgado, Javier, Luzardo Henriquez, Hugo, Sanz, Jaime, Calbacho, María, Bailén, Rebeca, Carpio, Cecilia, Ribera, Josep Maria, Sureda, Anna, Briones, Javier, Hernández Boluda, Juan Carlos, Martínez Cebrián, Nuria, Diez Martin, Jose Luis, Martín, Alejandro, Barba, Pere
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/199864
Acceso en línea:https://hdl.handle.net/2445/199864
Access Level:acceso abierto
Palabra clave:Cèl·lules B
Limfomes
B cells
Lymphomas
Descripción
Sumario:Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are CD19-targeted chimeric antigen receptor (CAR) T cells approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). We performed a retrospective study to evaluate safety and efficacy of axi-cel and tisa-cel outside the setting of a clinical trial. Data from consecutive patients with R/R LBCL who underwent apheresis for axi-cel or tisa-cel were retrospectively collected from 12 Spanish centers. A total of 307 patients underwent apheresis for axi-cel (n=152) and tisa-cel (n=155) from November 2018 to August 2021, of which 261 (85%) received a CAR T infusion (88% and 82%, respectively). Median time from apheresis to infusion was 41 days for axi-cel and 52 days for tisa-cel (P=0.006). None of the baseline characteristics were significantly different between both cohorts. Both cytokine release syndrome and neurologic events (NE) were more frequent in the axi-cel group (88% vs. 73%, P=0.003, and 42% vs. 16%, P<0.001, respectively). Infections in the first 6 months post-infusion were also more com -mon in patients treated with axi-cel (38% vs. 25%, P=0.033). Non-relapse mortality was not significantly different between the axi-cel and tisa-cel groups (7% and 4%, respectively, P=0.298). With a median follow-up of 9.2 months, median PFS and OS were 5.9 and 3 months, and 13.9 and 11.2 months for axi-cel and tisa-cel, respectively. The 12-month PFS and OS for axi-cel and tisa-cel were 41% and 33% (P=0.195), 51% and 47% (P=0.191), respectively. Factors associated with lower OS in the multivariate analysis were increased lactate dehydrogenase, ECOG >= 2 and progressive disease before lympho-depletion. Safety and efficacy results in our real-world experience were comparable with those reported in the pivotal trials. Patients treated with axi-cel experienced more toxicity but similar non-relapse mortality compared with those re-ceiving tisa-cel. Efficacy was not significantly different between both products.

Similares en LA Referencia